Trade Name: Hydrochlorothiazide

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: NuCare Pharmaceuticals, Inc.

Presentation: TABLET, HUMAN PRESCRIPTION DRUG

Strength: 25 mg/1

Storage and handling

HYDROCHLOROTHIAZIDE Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS]

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro-2 n n n n -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and has the following structural formula:n n nn
  • Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform, and in dilute mineral acids. Each tablet for oral administration contains 12.5 mg, 25 mg or 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: dibasic calcium phosphate dihydrate, FD & C yellow, lactose monohydrate, magnesium stearate, pregelatinized starch (starch 1500) and sodium starch glycolate.
  • The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure.
  • Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy.
  • Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.
  • After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.
  • Pharmacokinetics and Metabolism:
  • Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
  • Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
  • Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
  • Use in Pregnancy:
  • Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see n n n n n n ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.n nn n nn
  • Anuria.
  • Hypersensitivity to this product or to other sulfonamide-derived drugs.
  • Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.
  • Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
  • Thiazides may add to or potentiate the action of other antihypertensive drugs.
  • Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.
  • The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.
  • Lithium generally should not be given with diuretics (see n n n n n n ).n nn n nn
  • Acute Myopia and Secondary Angle-Closure Glaucoma:
  • All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
  • Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy.
  • Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmia and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium sparing diuretics or potassium supplements such as foods with a high potassium content.
  • Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis.
  • Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice. Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazides.
  • In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy.
  • The antihypertensive effects of the drug may be u00a0enhanced in the post-sympathectomy patient.
  • If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy.
  • Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.
  • Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.
  • Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.
  • The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.
  • Body as a Whole:
  • Cardiovascular:
  • Digestive:
  • Hematologic:
  • Hypersensitivity:
  • Metabolic:
  • Musculoskeletal:
  • Nervous System/Psychiatric:
  • Renal:
  • Skin:
  • Special Senses:
  • Urogenital:
  • Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.
  • The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
  • In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.
  • The oral LDn n n n n n of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat. n nn n nn
  • Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.
  • Adults:n n n n n n n
  • Arrayn- For Control of Hypertension:
  • Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive agents.
  • Infants and Children: n n n n n n n
  • Hydrochlorothiazide tablets, USP are available containing 25 mg hydrochlorothiazide, USP.
  • The 25 mg tablets are light orange to peach colored, round, flat tablets with beveled edges and debossed with H & 2 on either side of break line and another side is plain. They are available as follows:
  • Bottle of 30 tablets NDC 66267-106-30n n nBottle of 60 tablets NDC 66267-106-60n
  • Bottle of 90 tablets NDC 66267-106-90n n nBottle of 120 tablets NDC 66267-106-120n
  • Store at 20u00b0 - 25u00b0C (68u00b0 - 77u00b0F). [See USP for Controlled Room Temperature].
  • Dispense in a tight, light-resistant container as defined in the USP, using a child-resistant closure.
  • Manufactured For:
  • Manufactured By:
  • 10 9685 1 662364
  • Issued August 2015
  • No data

Ask for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of Hydrochlorothiazide (Hydrochlorothiazide) which is also known as Hydrochlorothiazide and Manufactured by NuCare Pharmaceuticals, Inc.. It is available in strength of 25 mg/1.

Hydrochlorothiazide (Hydrochlorothiazide) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE)

VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Are you an existing customer or a vendor of GNH India? Log in here to